Clinical trials: Multiple Sclerosis, Relapsing-remitting
Relapsing-Remitting Multiple Sclerosis
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric participants with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and…
- Trial name
- CONNECT (NCT02283853)
- Testing
- dimethyl fumarate, Interferon β-1a
- Where
- 62 sites in United States, Belgium and 16 more
- Volunteers
- 156 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Ireland Natalizumab (TYSABRI) Observational Program
The objectives of this study are to assess the long-term safety and impact on disease activity and progression of natalizumab (Tysabri) in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice…
- Trial name
- iTOP (NCT01943526)
- Testing
- natalizumab
- Where
- 5 sites in Ireland
- Volunteers
- 191 people
- Sponsor
- Biogen
MS (Multiple Sclerosis), Multiple Sclerosis (MS) - Relapsing-remitting
Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis
This observational study investigates if switching from MabThera® to Rixathon® is associated with changes in disease activity and/or safety in people with multiple sclerosis (MS).
- Conditions
- MS (Multiple Sclerosis), Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (Relapsing Remitting)
- Trial name
- NCT07235644
- Where
- Sweden
- Volunteers
- 184 people
- Sponsor
- Uppsala University
Relapsing-Remitting Multiple Sclerosis
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
This was an observational, single arm, multicentric study conducted for the adjustment of treatment strategy and its monitoring using high-frequency and high-dosage administration of interferon-beta (Rebif) in MS subjects.
- Trial name
- NCT01142453
- Testing
- Interferon beta 1a
- Volunteers
- 231 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden
This is an observational cohort study with retrospective analysis of prospectively collected data. The study cohort is constituted of all patients with relapsing-remitting multiple sclerosis (RRMS) treated with autologous stem…
- Trial name
- AutoMS-Swe (NCT05029206)
- Testing
- Autologous hematopoietic stem cell transplantation
- Where
- 8 sites in Sweden
- Volunteers
- 174 people
- Sponsor
- Uppsala University
Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
- Trial name
- SONICS (NCT03942952)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric…
- Trial name
- NCT03958877
- Testing
- BIIB017 (peginterferon beta-1a), Interferon beta type 1a
- Where
- 65 sites in United States, Argentina and 20 more
- Volunteers
- 152 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
- Trial name
- NCT04940065
- Testing
- Kesimpta
- Where
- 103 sites in Japan
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study to investigate whether baseline treatment with high-dose interferon beta 1a (Rebif 44 μg x 3 ), administered at a high frequency, leads to…
- Trial name
- RETURN (NCT01142518)
- Testing
- Interferon beta 1a
- Volunteers
- 86 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood.
- Trial name
- BIO-MS (NCT06195800)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS.
- Trial name
- NCT03870763
- Testing
- Dimethyl Fumarate, Peginterferon Beta-1a
- Where
- 23 sites in United States, Colombia and 11 more
- Volunteers
- 11 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to assess the efficacy of oral BG00012 as compared with placebo in pediatric subjects with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT02428218
- Testing
- dimethyl fumarate
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study on the extent to which subject compliance is influenced by use of a variable titration regimen at the start of treatment of relapsing MS…
- Trial name
- TOURIMS (NCT01142492)
- Testing
- Interferon beta-1a
- Volunteers
- 403 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
Significant data from placebo-controlled clinical trials have demonstrated the efficacy of Rebif in relapsing remitting multiple sclerosis (RRMS) with reduction in relapse rate, delay in disability progression, and reduction in…
- Trial name
- COMPARE (NCT01141751)
- Volunteers
- 334 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE
To provide real world evidence evaluating whether a strategy of early initiation and escalation of disease modifying treatment (DMT) in relapsing-remitting multiple sclerosis (RRMS) affects disease outcome over a 10 year period.
- Trial name
- MODERATE (NCT05446285)
- Testing
- Clinical assessment
- Where
- United Kingdom
- Volunteers
- 245 people
- Sponsor
- NHS Greater Glasgow and Clyde
Relapsing Remitting Multiple Sclerosis
Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS
The purpose of this study is to evaluate the benefits of a low-carbohydrate, high-fat diet (ketogenic diet) in up to 50 subjects with relapsing-remitting multiple sclerosis (RRMS), a chronic neuro-inflammatory disease.
- Trial name
- NCT03718247
- Testing
- Modified Atkins diet
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Virginia
Relapsing-remitting Multiple Sclerosis
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis
The aim of this observational study is to compare Dimethyl fumarate (DMF) and Teriflunomide on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from French Observatory of Multiple…
- Trial name
- COMP-RMS (NCT03302442)
- Testing
- Non interventional study
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Nantes University Hospital
Relapsing Remitting Multiple Sclerosis
Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS
In relapsing remitting multiple sclerosis (RRMS) the relationship between cognitive impairment (CI), fatigue and physical disability with white matter lesion load (WM-LL), location among other volumetric measures using automated…
- Trial name
- NCT05604092
- Testing
- VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures), Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- Assiut University
Multiple Sclerosis, Relapsing-Remitting
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200).
- Trial name
- NCT02555215
- Testing
- dimethyl fumarate
- Where
- 12 sites in United States, Belgium and 8 more
- Volunteers
- 20 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis (RRMS)
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
The Study analyses the influence of selected factors on adherence to Betaferon treatment in patients with early multiple sclerosis (MS).
- Trial name
- BEACON (NCT00787657)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 36 sites in Argentina, Bahrain and 34 more
- Volunteers
- 1,723 people
- Sponsor
- Bayer